1-6 of 6
Brian Elliot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik
Journal: Blood
Blood (2022) 140 (Supplement 1): 12108–12109.
https://doi.org/10.1182/blood-2022-157596
Published: 2022
Journal Articles

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Lorenzo Falchi, Franck Morschhauser, John G. Gribben, Huiqiang Huang, Minh Dinh, Rebekah Conlon, Xiaorong Chen, Brian Elliot, John F. Seymour
Journal: Blood
Blood (2022) 140 (Supplement 1): 9338–9339.
https://doi.org/10.1182/blood-2022-157584
Published: 2022
Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Tycel Phillips, Catherine Thieblemont, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana A. Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Limei Poon, Nurgul Kilavuz, Mariana Cota Stirner, David Soong, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliot, Martin Hutchings, Pieternella Lugtenburg
Journal: Blood
Blood (2022) 140 (Supplement 1): 9443–9445.
https://doi.org/10.1182/blood-2022-158245
Published: 2022
Journal Articles

Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

Kim M Linton, Björn Wahlin, Sirpa Leepä, Franck Morschhauser, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3535.
https://doi.org/10.1182/blood-2021-146629
Published: 2021
Journal Articles

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

David Belada, Jacob Haaber Christensen, Kristina Drott, Sylvia Snauwaert, Joshua Brody, Mayur Narkhede, Fritz Offner, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi, Michael Roost Clausen
Journal: Blood
Blood (2021) 138 (Supplement 1): 1413.
https://doi.org/10.1182/blood-2021-146569
Published: 2021